IL-13 antagonists in the treatment of atopic dermatitis

Immunotherapy ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 327-344
Author(s):  
Carla Tubau ◽  
Lluís Puig
Keyword(s):  
Monoclonal Antibody ◽  
Clinical Trials ◽  
Atopic Dermatitis ◽  
Small Molecules ◽  
Skin Disease ◽  
Skin Diseases ◽  
Inflammatory Skin Disease ◽  
Receptor Alpha ◽  
Inflammatory Skin

Atopic dermatitis (AD) is a prevalent inflammatory skin disease. IL-13 contributes significantly to the pathogenesis of AD in several ways, and beneficial results have been demonstrated with anti-IL-13 therapies. Currently, the only monoclonal antibody (mAb) approved for AD treatment is dupilumab, an antagonist of the IL-4 receptor alpha (IL-4Rα) subunit common to IL-4 and IL-13 receptors, but clinical trials evaluating anti-IL-13 mAbs are providing promising results. The topics of this review will be mAbs targeting IL-13 for the treatment of AD such as dupilumab, tralokinumab and lebrikizumab, small molecules targeting the IL-13 pathway, and a brief explanation of therapies targeting IL-13 for the treatment of other skin diseases.

scholarly journals COVID-19 and Psoriasis: A Concise Systematic Review

2021 ◽  
Vol 2 (4) ◽  
Author(s):  
Michelle Silva Rocha ◽  
Lorenna Lemos de Aquino ◽  
Ágda Tamires da Silva Rodrigues ◽  
Clarice Paiva de Oliveira ◽  
Lívia Mendes Montoya Lazo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Skin Disease ◽  
Health Care Services ◽  
Skin Diseases ◽  
Clinical Course ◽  
Immunosuppressive Agents ◽  
Inflammatory Skin Disease ◽  
Biological Products ◽  
Dermatological Disease ◽  
Inflammatory Skin

Introduction: The effects on human health caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) lead to hyperinflammation processes, which can lead to meta-inflammation. This process can aggravate skin diseases, especially psoriasis. This is a chronic inflammatory skin disease associated with significant morbidity. This problem affects about 2-3% of people worldwide. Objective: to demonstrate, through a concise systematic review, the main considerations about the relationship between COVID-19 and psoriasis, showing the possible mechanisms for the worsening of this dermatological disease. Methods: The research was carried out from June 2021 to July 2021 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar, following the Systematic Review-PRISMA rules. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results: Psoriasis is a common chronic inflammatory skin disease and is autoimmune. Patients with COVID-19 may have features of hyper inflammation and even meta-inflammation. The triggering or exacerbating factor of psoriasis may be medications and, in addition, patients with COVID-19 may have psoriasis exacerbation. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease. It is envisioned that the use of azithromycin in cases of COVID 19 with pre-existing psoriasis can alleviate psoriatic lesions. Conclusion: The COVID 19 pandemic had a direct impact on dermatological diseases, especially psoriasis. Difficulty in accessing health care services and the stress load caused exacerbations in psoriasis cases. Studies recommend avoiding classic immunosuppressive agents such as methotrexate, cyclosporine, and TNF alpha inhibitors. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease.

Therapeutic Approach of Probiotic in Children with Atopic Dermatitis

2020 ◽  
Vol 19 ◽  
Author(s):  
Sangeeta Huidrom
Keyword(s):  
Atopic Dermatitis ◽  
Skin Disease ◽  
Developed Countries ◽  
Current Treatment ◽  
Inflammatory Skin Disease ◽  
Social Burden ◽  
The Family ◽  
Prevention And Treatment ◽  
Inflammatory Skin ◽  
Chronic Skin

: Pediatric atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease affecting 20% of children all over the world especially in developed countries. Recently, there is an increase in the prevalence rate of AD. This chronic inflammatory skin disease causes economic and social burden to the family. The exact cause of AD is not known, however recent studies suggest that imbalance of microflora present in the gut leads to AD. The current treatment of AD involves the application of moisturizer, topical corticosteroids, antihistamines and antibiotics. This line of treatment of AD in children has many side effects. An alternative novel therapeutic approached have to be explored to combat this chronic skin disease. In recent years there is increasing interest in the use of probiotic in the modulation of gut microbiota for the management of AD. Many research studies showed that administration of probiotic give positive results in the prevention and treatment of AD in children, however, the results are not consistent and conclusive. In this review, the dysbiosis of the gut flora contributes to the development of AD is addressed and clinical evidence of probiotics in the prevention and treatment of AD children is also summarises.

scholarly journals ATOPIC DERMATITIS: DIAGNOSTICS FEATURES

2012 ◽  
Vol 9 (2) ◽  
pp. 35-44
Author(s):  
D Sh Macharadze
Keyword(s):  
Atopic Dermatitis ◽  
Broad Spectrum ◽  
Skin Disease ◽  
Environmental Control ◽  
Clinical Symptoms ◽  
Food Allergens ◽  
Inflammatory Skin Disease ◽  
Allergen Avoidance ◽  
Inflammatory Skin

Atopic dermatitis (AD) — a chronic inflammatory skin disease with a broad spectrum of clinical symptoms. It is diagnosed mainly clinically. Sensitization to inhalled and food allergens may play a role in the development of AD. Thus, it is important to determine the presence of sensitization for environmental control and allergen avoidance, pharmacotherapy, and immunotherapy.

scholarly journals The role of Dwaya Haridra with Nimbadi tail in the management of of vicharchika W.S.R. to Eczema

2021 ◽  
Vol 5 (02) ◽  
Author(s):  
Dr. Subhash B. Jamdhade ◽  
Namrata kende ◽  
Dr. S. K. Jaiswal ◽  
Dr. Pradnya. S. Jamdhade
Keyword(s):  
Atopic Dermatitis ◽  
Skin Disease ◽  
Skin Diseases ◽  
Skin Condition ◽  
Inflammatory Skin ◽  
Scaly Skin

ABSTRACT In ayurveda all skin diseases describes under the heading of kushta .  "Kushnatee iti kushtham."       ( Ma.Ni/kushta/Tika 1) The disease that destroyes the affected part of skin . Both charak samhita and sushrut samhita  classify skin disease into 2 categories . 1) Mahakushtha (major) 2) Kshudrakushtha (minor)                                               ....... Ch.ni 5/4 Ayurvedically, Eczema is considered to be a type of kushtha. i. e.type of kushdrakushtha which is disease of the skin .It is also known as a type of twak roga .which also signifies that it is a skin disease that twak translates to skin and rog translates to pain . Vicharchika is characterised by the following symptoms ati kandu ,bahu strav ,rukshta ,shyavata ,pidika,raji. As described in terms od nidan ,purvarupa,samprapti and chikitsa vicharchika can most certainly be corelated with the modern interpretation of eczema or atopic dermatitis .Eczema or atopic dermatitis is chronic inflammatory skin condition. Atopic dermatitis is characterised by  cracked or scaly skin discolored patches,erythma(red skin),papules, exudate(oozing) and intence pruritus (itching ).

scholarly journals Efficacy of topical agents in the background therapy of atopic dermatitis in children

2018 ◽  
pp. 122-127 ◽  
Author(s):  
E. I. Danilova ◽  
O. Yu. Trusova ◽  
V. V. Sumenko
Keyword(s):  
Atopic Dermatitis ◽  
Skin Reaction ◽  
Skin Disease ◽  
Topical Agent ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Inflammatory Skin Disease ◽  
Background Therapy ◽  
The Mean ◽  
Inflammatory Skin

Atopic dermatitis (AtD) is a chronic inflammatory skin disease with complex etiopathogenesis, which begins in childhood. Purpose of the study: To evaluate the clinical efficacy and safety of Skin-cap cream as a topical background therapy in children with diabetes. Materials and methods: The study included 77 children aged 1 to 11 years with moderately severe AtD with a widespread lesion of the skin (33,5%), skin itching, inflammatory skin reaction and exacerbations occurring 3 to 4 times a year. During the study, two arms of children were formed: the treatment arm - 39 children with an average course of the disease (SCORAD index = 33,9 ± 2,2 points), who received the background therapy with the prescription of Skin-cap cream. Comparison arm: 38 children (SCORAD index = 34,2 ± 2,1 points), who received Afloderm cream as a background therapy. Results: Patients of the treatment arm showed a significant dynamics of relief of AtD symptoms as compared with the comparison arm. the differences in the duration of dermal manifestations were as follows: in the treatment arm, the time of reducing hyperaemia was 4,4 ± 1,2 days, in the comparison arm, hyperaemia was reduced at 5,7 ± 1,5 days (p< 0.05), the mean duration of alleviation of the skin itching was 3,0 ± 0,9 days and 5,8 ± 1,4 days (p< 0,05) at 6,8 and 7,3 days in the treatment arm and the comparison arm, respectively. Conclusions: The conducted study confirmed the high efficacy of the use of Skin-cap cream as a topical agent for background therapy of AtD, as compared to topical glucocorticosteroids.

scholarly journals From Emollients to Biologicals: Targeting Atopic Dermatitis

2021 ◽  
Vol 22 (19) ◽  
pp. 10381
Author(s):  
Lorenzo Salvati ◽  
Lorenzo Cosmi ◽  
Francesco Annunziato
Keyword(s):  
Atopic Dermatitis ◽  
Skin Disease ◽  
Clinical Presentation ◽  
Age Groups ◽  
Inflammatory Skin Disease ◽  
Clinical Phenotypes ◽  
Inflammatory Skin

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and significantly impacts patients’ lives, particularly in its severe forms. AD clinical presentation varies over the course of the disease, throughout different age groups, and across ethnicities. AD is characterized by a spectrum of clinical phenotypes as well as endotypes. Starting from the current description of AD pathogenesis, this review explores the rationale of approved AD therapies from emollients to biologicals and introduces novel promising drugs.

scholarly journals Evidence of a common causal relationship between body mass index and inflammatory skin disease: a Mendelian Randomization study

2018 ◽  
Author(s):  
Ashley Budu-Aggrey ◽  
Ben Brumpton ◽  
Jess Tyrrell ◽  
Sarah Watkins ◽  
Ellen H Modalsli ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Causal Relationship ◽  
Body Mass ◽  
Skin Disease ◽  
Skin Diseases ◽  
Mendelian Randomization ◽  
Uk Biobank ◽  
Inflammatory Skin Disease ◽  
Level Data ◽  
Inflammatory Skin

ABSTRACTObjectivePsoriasis and eczema are common inflammatory skin diseases that have been reported to be associated with obesity. However, causality has not yet been established. We aimed to investigate the possible causal relationship between body mass index (BMI) and psoriasis or eczema.MethodsFollowing a review of published epidemiological evidence of the association between obesity and either psoriasis or eczema, Mendelian Randomization (MR) was used to test for a causal relationship between BMI and these inflammatory skin conditions. We used a genetic instrument comprising 97 single nucleotide polymorphisms (SNPs) associated with BMI. One-sample MR was conducted using individual-level data (401,508 individuals) from the UK Biobank and the Nord-Trøndelag Health Study (HUNT), Norway. Two-sample MR was performed with summary-level data (731,021 individuals) from published BMI, psoriasis and eczema GWAS. The one-sample and two-sample MR estimates were meta-analysed using a fixed effect model. To explore the reverse causal direction, MR analysis with genetic instruments comprising variants from recent genome-wide analyses for psoriasis and eczema were used to test if inflammatory skin disease has a causal effect on BMI.ResultsPublished observational data show an association of greater BMI with both psoriasis and eczema case status. The observational associations were confirmed in UK Biobank and HUNT datasets. MR analyses provide evidence that higher BMI causally increases the odds of psoriasis (by 53% per 5 units higher BMI; OR= 1.09 (1.06 to 1.12) per 1 kg/m2; P=4.67×10-9) and eczema (by 8% per 5 units higher BMI; OR=1.02 (1.00 to 1.03) per 1 kg/m2; P=0.09). When investigating causality in the opposite direction, MR estimates provide little evidence for an effect of either psoriasis or eczema influencing BMI.ConclusionOur study, using genetic variants as instrumental variables for BMI, shows that higher BMI leads to a higher risk of inflammatory skin disease. The causal relationship was stronger for psoriasis than eczema. Therapies and life-style interventions aimed at controlling BMI or targeting the mechanisms linking obesity with skin inflammation may offer an opportunity for the prevention or treatment of these common skin diseases.

Sign in / Sign up

Export Citation Format

Share Document